End-Stage Renal Disease (ESRD) Market Size, Share, Growth Analysis, By Treatment(Dialysis, Kidney and Transplantation), By End-user(hospitals and clinics, and home care settings), By Region - Industry Forecast 2024-2031

Global End-Stage Renal Disease Market size was valued at USD 99.2 Billion in 2022 and is poised to grow from USD 112.2 Billion in 2023 to USD 300.38 Billion by 2031, at a CAGR of 13.10% during the forecast period (2024-2031).

The increasing number of individuals suffering from kidney failure and the introduction of advanced medical devices, such as low-maintenance dialysis equipment and artificial kidneys, are key drivers of this market. Chronic Kidney Disease (CKD) is a major cause of kidney failure, often resulting from conditions that lead to reduced kidney function. CKD can gradually develop over time and eventually progress to ESRD, also known as kidney failure. Factors such as hypertension, diabetes, smoking, and the aging population contribute to the development of ESRD, with diabetes being the most common cause and hypertension being the second-most frequent cause. Treatment options for ESRD/CKD include kidney transplantation or dialysis to sustain life. CKD has a high incidence rate globally, with approximately 10% of the global population suffering from the condition, leading to millions of deaths each year. The geriatric population in developing countries, such as China and India, is particularly affected. The number of patients requiring kidney transplants or dialysis is increasing at a rate of 5-7% annually. The prevalence of CKD is higher in women than men, and the rising number of individuals with hypertension and diabetes further contributes to the growth of the market. Diabetes is the primary cause of advanced kidney disease, followed by hypertension, affecting approximately 1 billion individuals worldwide. Baxter, a prominent company in this market, has announced strategic initiatives to enhance operational effectiveness and innovation, including spinning out their renal care and acute treatments global business units into a separate organization.

Regions like Africa, China, the Rest of Asia Pacific, the U.S., Taiwan, Japan, Germany, France, and Belgium have observed a high prevalence of ESRD in recent years. In the U.S., around 80 million people, or 1 in 3 adults, are at risk of CKD, making it the ninth leading cause of death. Developing countries like China and India are projected to witness an increase in cases of renal failure, particularly among the elderly population. The market growth is further supported by technological advancements in the treatment of renal failure. For example, the approval of human clinical trials for the Wearable Artificial Kidney 2.0 by the U.S. FDA in 2014 showcases the development of innovative blood purification technologies for kidney failure patients. The presence of numerous hospitals and a well-developed healthcare infrastructure in the U.S. also contributes to market growth. With a significant number of hospital admissions for acute kidney injury (AKI), there is a growing demand for dialysis and transplantation. Additionally, the number of dialysis clinics and treatment centers is increasing, with approximately 7,500 dialysis clinics currently operating in the U.S.

US End-Stage Renal Disease (ESRD) Market is poised to grow at a sustainable CAGR for the next forecast year.